TMC647055: Phase IIa data

Medivir AB (SSE:MVIR B, Huddinge, Sweden) reported data from the open-label, European Phase IIa HPC2001 trial in patients with chronic HCV genotype 1 infection evaluating an all-oral regimen of once-daily Olysio simeprevir plus TMC647055 and low-dose ritonavir with or without 30 or 60 mg JNJ-56914845 for 12 weeks. In patients who received Olysio plus TMC647055 and low-dose ritonavir with ribavirin, up to 86% achieved an SVR12. In patients who received Olysio plus TMC647055 and low-dose ritonavir without ribavirin, up to 50% achieved an SVR12. In patients who received Olysio plus TMC647055 and low-dose ritonavir with 30 mg JNJ-56914845 (n=22), 82% achieved an SVR12. In patients who received Olysio plus TMC647055 and low-dose ritonavir with 60 mg JNJ-56914845 (n=22), 95% achieved an SVR12. Data were presented at the Asian Pacific Association for the Study of the Liver meeting in Istanbul. ...